Swiss pharma company Helsinn Group and MEI Pharma, Inc. (MEIP) announced Thursday that they have decided to discontinue the recruitment of patients and end the Phase 3 Study with Pracinostat in Acute Myeloid Leukemia (AML) following an interim analysis.
from RTT - Biotech https://ift.tt/3ipVxnx
via IFTTT
No comments:
Post a Comment